Heart failure & cardiomyopathiesRandomised controlled trial

Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial

CirculationPublished

  • Randomised controlled trial
  • investigator-initiated
  • prospective
  • multicentre
  • double-blind

Authors' conclusion

Proprotein convertase subtilisin/kexin 9 inhibition with alirocumab in addition to statin therapy early after HT safely lowers low-density lipoprotein cholesterol but did not reduce coronary artery plaque progression after 1 year compared with rosuvastatin alone in patients with a low baseline low-density lipoprotein cholesterol.

Study context

Population
Heart transplant recipients, randomised early after heart transplantation (HT)
Participants
114 recipients
Comparison
Alirocumab vs placebo, in addition to rosuvastatin
  • Alirocumabn = 57
  • Placebon = 57reference
Primary endpoint
Change in coronary artery plaque volume on serial intravascular ultrasound
Follow-up
Baseline to 1 year after HT

Primary result

As reported in the abstract

Change in coronary plaque volume (serial IVUS) · 1 year
GroupPlaque volume baseline → 12 monthsP (within group)
Alirocumab176.3±95.2 to 184.5±105.4 mm³P=0.23
Placebo173.7±96.7 to 183.1±109.8 mm3P=0.15
Change in plaque volume (mean difference in differences) did not differ between groups
1.01 [0.89-1.14]; P=0.86

Further findings

OutcomeAlirocumabPlacebo
LDL-C · baseline to 1 year72.7 to 31.5 ± 31.7–20.7 mg/dL69.0 to 69.2 ± 22.4–28.1 mg/dL
within-group PP<0.001P=0.92

Fractional flow reserve, coronary flow reserve, index of microcirculatory resistance

No significant change with the addition of alirocumab

Safety

Adverse events related to alirocumab

No significant adverse events related to alirocumab

Original publication

Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial. Circulation. Published 10 November 2025. doi:10.1161/circulationaha.125.077603

Summarised from the published abstract; every number is checked against it